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Abstract
In clinically suspected urinary tract infections (UTIs), empirical antibiotic treatment is usu-
ally started long before the laboratory results of urine culture and antibiogram are avail-
able. Although molecular diagnostic approaches are being applied to the diagnosis of many 
infections, UTIs are generally diagnosed by traditional culture methods. Patient care could 
greatly benefit from the development of a rapid, accurate, inexpensive test that could be 
done at patient’s bedside, allowing the practitioner to plan targeted, more effective therapy. 
Such a test would potentially reduce incorrect or unnecessary use of antibacterial drugs 
and reduce the emergence of bacterial resistance. In response to this pressing and unmet 
clinical need, several methods have been developed in the last few years. Among these, the 
new point-of-care test (POCT) for detecting UTIs named Micro Biological Survey (MBS) 
UTI CHECK holds promise, as it allows semi-quantitative determination of bacterial load 
in urine leading to a fast detection of UTIs and to evaluation of bacterial antibiotic suscepti-
bility. This new technology operates through a colorimetric survey performed in low-cost, 
ready-to-use, disposable vials, in which 1 ml of urine is inoculated without any preliminary 
treatment and requiring neither specialized personnel nor a specialized equipment.
Keywords: urinary tract infections, point-of-care test, clinical microbiology analysis, 
UTIs diagnosis, antimicrobial resistance
1. Introduction: definition and background over urinary tract 
infections (UTIs)
Urinary tract infections (UTIs) are caused by the presence and multiplication of microorgan-
isms in the urinary tract, sometimes spreading to the bloodstream and possibly resulting in sev-
eral clinical syndromes (e.g., pyelonephritis, cystitis, urethritis, epididymitis and prostatitis) [1].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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Most UTIs are caused by bacteria, and when they occur in the urine without causing symp-
toms, this condition is called asymptomatic bacteriuria; when growth of bacteria leads to a 
panel of symptoms, this condition is referred to as symptomatic bacteriuria [1]. Urinary tract 
infections can manifest as bacteriuria with limited clinical symptoms and sepsis, depending 
on localized or systemic extension [2].
The onset of UTIs is mostly due to the ascent of microorganisms from the urethra, especially 
organisms of enteric origin, e.g., Escherichia coli, which is the causative pathogen in 70–95% 
of acute, uncomplicated UTIs in adults, followed by other Enterobacteriaceae, such as Proteus 
mirabilis and Klebsiella spp., and by Staphylococcus saprophyticus in 5–10% of cases [2]; hence, 
the higher frequency of UTIs in women than men, depending on anatomic structure, and 
the increased risk of infection following bladder catheterization, which compromises natural 
defense mechanisms. A small fraction of UTIs can have hematogenous origin, and usually 
involve a few relatively uncommon microorganisms (e.g., Staphylococcus aureus, Candida spp., 
Salmonella spp. and Mycobacterium tuberculosis), which cause primary infections elsewhere in 
the body and thus reach the urinary tract [2].
UTIs are among the most prevailing infectious diseases with a substantial financial burden on 
society [3]. The incidence of community-acquired UTIs is highest in young women [1]: almost 
half of all women will experience at least one episode of UTI during their lifetime, and nearly 
1 in 3 women will have had at least one episode of UTI by the age of 24 years [2]. Urinary tract 
infection incidence increases with age for both sexes. It is estimated that 10% of men and 20% 
of women over the age of 65 years have asymptomatic bacteriuria [1].
Reports from European countries and the USA show that ca. 15% of all community-pre-
scribed antibiotics are dispensed for UTIs [3]. UTIs account for many annual hospital 
admissions, especially among the elderly: in the UK, the number of emergency admissions 
of older people with a primary diagnosis of UTI showed a 200% increase from 2001/2002 
to 2012/2013, parallel to a related increase in bed days, which both are the second high-
est increase (in absolute terms) among groups of conditions [4]. Nevertheless, UTIs are 
believed to have been greatly overcoded in recent years: part of the increase may be due 
to changes in coding practice, part to increased emergence of antibiotic resistance [4]. 
Moreover, UTIs represent at least 40% of all hospital acquired infections and most of them 
occur following catheterization, which is considered one of the main risk factors associated 
to onset of UTIs [3].
2. Current laboratory standards in UTI diagnosis
The clinical evidence of UTI is based on a number of basic criteria, including clinical symp-
toms, and laboratory data which should provide evidence of the presence of microorganisms 
by culturing of urine samples, or other specific tests [2]. However, the diagnosis of UTIs is 
primarily based on symptoms and signs. Tests that suggest or prove the presence of bacte-
ria or white cells in the urine may contribute additional information to inform management 
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but rarely have important implications for diagnosis, also considering the long time often 
required for obtaining results with traditional methods [5].
The gold standard for diagnosis of bacteriuria is culture of appropriate urine sample [6, 7]. 
Sampling by needle aspiration minimizes the risk of contamination, while catheter and mid-
stream sampling show a higher risk of contamination and therefore yield more false positive 
results [5]. However, needle aspiration is invasive and midstream sampling is preferred in 
clinical practice [8]. Routine culture is generally carried out streaking 10 μl of urine sample 
on agar plates containing selective or differential media and reading results after at least 
24–48hours of incubation, considering characteristic colony morphologies and average quan-
titation. If there is the need for more accurate quantitative results, 100 μl plating following 
serial dilutions of urine sample must be performed [9]. The main value of urine culture is to 
identify microorganisms, most often bacteria; indirect indicators of the presence of bacteria 
(for example, urinary nitrites) are much less valuable than urine culture [5].
The number of bacteria in urine has been considered relevant for the diagnosis of UTIs since 
the Sixties, when Kass developed the concept of significant bacteriuria (105 CFU/ml) open-
ing up to quantitative microbiology for the diagnosis of infectious diseases; his notion is still 
generally used to help diagnosis. Nevertheless, it has recently become clear that no fixed 
bacterial count can be applied to all kinds of UTIs and all circumstances, and even low bac-
terial concentrations are considered clinically relevant considering specific clinical pictures, 
sampling protocols and patient’s sex. The problem of counting low numbers must then be 
considered [2].
Along with pathogen identification, outlining its antimicrobial susceptibility profile is consid-
ered to be crucial to ensure an appropriate treatment [10]. Antimicrobial susceptibility testing is 
routinely performed using the Kirby-Bauer disk diffusion technique according to Clinical and 
Laboratory Standards Institute (CLSI) guidelines, meaning culturing bacteria from urine sam-
ples on agar plates in presence of disks containing selected antibiotics; interpretation of results 
requires the measurement of halos of inhibition around disks according to reference tables [11].
As with most bacterial infections, diagnosis of UTI depends on culturing the clinical sample 
in the clinical laboratory, and results are typically delayed of two to three days from sample 
acquisition [10]. This is due to the need for sample transport to the laboratory and the time 
required for bacteria to grow on culture media [10]. Thus, the standard method for UTI diag-
nosis is time consuming and logistically difficult [6].
Since the patient cannot remain untreated during this rather prolonged period before 
definitive diagnosis is obtained, physicians usually prescribe broad spectrum antibiotics 
prior to antibiogram results. This practice has many undesirable consequences in the short 
and long terms, such as treatment failure leading to spread or chronicization of infection, 
increased health care costs, and increased antibiotic resistance by a growing number of bac-
terial strains. Given these drawbacks, it is obvious that a rapid and accurate method of UTI 
diagnosis and bacterial antibiotic susceptibility assessment would offer significant health 
benefits [12].
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The introduction of partial and complete automation in clinical diagnostic in the 2000s has allowed 
the management of large-scale sample volumes and workflows optimization still providing reli-
able results for both pathogen identification and antibiotic susceptibility testing [10, 13].
Large-scale systems, anyway, are expensive and require more dedicate space, equipment and 
more personnel competence, which makes them applicable to a large hospital setting, but are 
difficult to establish in a small hospital, or in a limited-resource setting (e.g., developing coun-
tries). These high-throughput culture-based instruments, moreover, remain relatively slow 
and are not amenable for point-of-care use [10].
The introduction of matrix-assisted laser desorption/ionization time-of-flight mass spec-
trometry (MALDI-TOF) technology in microbiology has allowed rapid and reliable bacterial 
identification, featuring both high sensitivity and specificity, improving efficiency and saving 
consumables and labor [14, 15]. MALDI-TOF technique is usually coupled with culture of 
urine samples, to allow isolation of bacteria and therefore obtain pure cultures, which will 
undergo MALDI-TOF analysis after some sample treatment. Recently, extensive databases 
have been developed that include protein profiles of main microorganisms involved in infec-
tions; some studies have therefore investigated the possibility to apply MALDI-TOF analy-
sis directly to urine samples, yielding promising results also when coupling such analysis 
with screening methods, such as automated microscopic urine sediment analysis [16, 17]. It 
must be considered, however, that such high-throughput technology has high installation 
and maintenance costs, and requires dedicated spaces, limiting its use in routine analyses 
to centralized laboratories. Moreover, the technique cannot currently identify two species of 
bacteria when present simultaneously, and cannot determine antibiotic susceptibility; thus, 
traditional culture of urine samples is still necessary [18].
Nevertheless, the occurrence of more than one bacterial strain in urine samples participating in 
the infection should not be overlooked. Polymicrobic infections are more often associated with 
catheterization and aging, reaching 10% incidence rates in the community and 30% in hos-
pital setting among elderly people [19]. Bacterial strains recovered from polymicrobic infec-
tion show metabolic alterations and altered virulence traits, such as antibiotic resistance [19]. 
However, relationships between coinfecting strains are not yet fully understood [20], although 
some studies are exploiting such infections’ mechanisms [21, 22]. As clinical laboratories 
tend to report cultures showing single or clearly predominant bacteria and will not routinely 
report occurrence of polymicrobic associations, unless significant numbers of each species are 
detected, quite a large portion of UTIs are not correctly diagnosed nor treated, threatening 
patient’s safety [19, 23–25]. Therefore, an improvement of diagnosis and clinical pathways 
is needed in order to enhance not only detection of pathogens in urine, but also profiling the 
whole microflora and determining the antimicrobial susceptibility of individual components.
3. When a urine culture followed by antibiogram is needed
Even though the incidence of UTIs is higher in women [6], also related pathologies in men, such 
as epididymitis and prostatitis, may be caused by migration of pathogens from the urethra or 
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bladder, the most common pathogens isolated being Chlamydia trachomatis, Enterobacteriaceae 
(typically E. coli) and Neisseria gonorrhoeae. For this last species, to reach correct diagnosis and 
plan following treatment, culture of mid-stream urine should be performed, together with 
nucleic acid amplification test (NAAT) on first voided urine or Gram staining in order to spe-
cifically detect Neisseria gonorrhoeae or Chlamydia trachomatis [6, 26].
Urine culture is recommended to determine the presence or absence of clinically significant 
bacteriuria in patients prior to urological interventions (e.g., surgery) and the presence of 
bacteriuria is controlled by directed pre-operative treatment of the detected pathogen [2, 6].
Urine culture is considered a valuable tool during patients’ follow-up: in women whose 
symptoms do not resolve or recur within 2–4 weeks after the completion of treatment, urine 
culture and antimicrobial susceptibility test should be performed and a new antibiotic regi-
men should be considered. Afterward, in patients who underwent antibiotic treatment, a fol-
low-up with subsequent urine culture should verify the treatment efficacy [2]. Urine culture 
is also recommended in women who present with atypical symptoms, pregnant women and 
males with suspected UTI [2].
In case of complicated UTIs, a broader range of bacteria is expected to be involved (often 
within the Enterobacteriaceae family), and these are more likely to show antibiotic resistance. 
Moreover, patients with a complicated UTI are more prone to have recurrent infections (more 
than 3 episodes/year) [2, 8, 27, 28]. Therefore, the choice of a therapy for these conditions must 
be supported by urine culture and antimicrobial susceptibility testing to avoid ineffective 
antibiotics administration.
Urine culture is also required in pediatric settings, where UTIs are the most common infec-
tions in children and infants, together with upper respiratory and gastrointestinal ones, with 
30% recurrence rate reported within a year after initial UTI [2, 29]. Diagnosing pediatric UTIs 
may be difficult, because of communication difficulties in describing symptoms and vague-
ness of signs in small children; therefore, the definitive diagnosis of infection in children 
requires a positive urine culture [2].
In febrile patients with negative results on dipstick, microscopic, or automated urinalysis, 
urine culture is unnecessary if there is an alternative cause of the fever or inflammatory signs. 
However, if the dipstick and/or urinalysis are positive, confirmation of UTI by urine culture is 
mandatory [29]. In febrile children with signs of UTI (clinical signs, positive dipstick and/or pos-
itive microscopy, better if urine culture is available), antibiotic treatment should be initiated as 
soon as possible to eradicate the infection, prevent bacteremia, improve clinical outcome, dimin-
ish the likelihood of renal involvement during the acute phase of infection, and reduce the risk 
of immediate and long-term complications, including renal scarring and renal failure [29, 30].
4. Empirical treatment of UTIs
The gold standard for diagnosis and successful management of UTIs is to obtain identification 
and quantification of the infecting agents, along with antibiotic susceptibility assessment to 
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direct a specific therapy [31]. The use of microbiological culture method is well established 
in the diagnosis of infectious diseases [32]; however, such reference method is time-consum-
ing, requiring on average 24–48hours, thus laboratory results are not immediately available, 
especially at patient’s presentation in the Emergency Department [32, 33]. For this reason, in 
order to avoid even serious complications (e.g., sepsis) and mitigate patients’ discomfort, 
the initial treatment specified by international guidelines as first step in UTIs management is 
most often empirical [32]. Nevertheless, this empirical approach contributes to mis- and over-
use of antibiotics [10], resulting from unnecessary or inappropriate antimicrobial therapy, 
participating in recent arise in bacterial resistance. In fact, for people with symptoms of UTI 
and bacteriuria the main aim of treatment is relief of symptoms, but in case of unsuccessful 
treatment it could cause some alteration of urinary tract microflora, leading to an increased 
risk of clinical adverse events, including infections with multi-drug-resistant organisms and 
the development of antibiotic-resistant UTIs [1]. Infections caused by multi-drug-resistant 
pathogens, such as extended-spectrum beta-lactamase (ESBL) and carbapenemase producing 
Gram-negative bacteria, methicillin-resistant Staphylococcus aureus (MRSA), and bacteria resis-
tant to broad-spectrum antibiotics, such as fluoroquinolones and cephalosporins, are indeed 
increasingly recorded among UTIs and are the cause of a serious challenge to the public health 
system today [2, 10, 34].
The spread of antibiotic resistance is a threat to patients undergoing urological surgery in 
general [2], and multi-drug-resistant bacterial infections can limit the availability of effective 
treatment options, especially in low-income countries, rendering some UTIs difficult to treat 
and increasing healthcare costs [30].
This situation is generally promoted by several factors, including the overuse and misuse of 
antimicrobials in human and veterinary medicine and, indirectly, in agriculture. Measures to 
prevent and control the increase of antimicrobial resistance as well as the dissemination of 
resistance genes are crucial [35]. Prudent prescribing and rational use of antibiotics is a key 
component of action plans for reducing antimicrobial resistance [1, 2, 35, 36]. Antimicrobial 
stewardship programs have become a priority to optimize the outcome of prevention and 
treatment of infection while limiting overuse and misuse of antimicrobial agents [6], also fol-
lowing a systematic audit approach [37, 38]. In addition, non-antibiotic strategies are being 
explored [6]. There are many non-antimicrobial measures recommended, especially for recur-
rent UTIs [2, 28, 39, 40], but only a few results from well-designed studies are available for 
evidence-based recommendations [2, 41].
In general, the choice of antibiotics should be based, among other factors, upon identification 
and susceptibility pattern of the organism causing the UTI and the ecological collateral effects 
including selection of resistant bacteria by the chosen antimicrobial [2].
It must be considered, though, that the in vitro susceptibility of community-acquired uro-
pathogens varies according to age and geographic region, and, as magnitude and variability 
of antimicrobial resistance patterns in the community grow, so does the need for continuous 
large-scale surveillance systems, in order to create databases linking epidemiological, clinical 
and laboratory data [42].
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Therefore, the development and implementation of new clinical tools in routine medical prac-
tice could help optimizing antibiotic administration, leading to a more prudent and rational 
use of antibiotics. A rapid screen may be a more practical approach to yield benefits for the 
patient, the physician, and the laboratory [43].
The advent of new innovative diagnostic devices for UTI management, complementary to 
the reference culture-based methods, may lead to a new deal improving routine practice. 
Immunocompromised patients (e.g., diabetes mellitus, chronic kidney disease, and kidney 
transplant) with UTIs could particularly benefit from such diagnostic improvements. Clinical 
diagnosis of UTIs in this category of patients is challenging, because causative pathogens 
may be slightly different to those in the general population, and because of patients’ clinical 
picture complexity. Early diagnosis is imperative in this group, and treatment of UTIs should 
be tailored according to individual patient characteristics [44].
5. Alternative and non-culture-based methods for the detection of UTIs
Because of the clinical importance of early UTI diagnosis, alternative rapid near-patient urine 
tests have been developed, such as urine dipsticks, which are widely used [31] in spite of their 
uncertain diagnostic accuracy [6]. The urine dipsticks test is commonly used for presumptive 
diagnosis of UTIs: it detects the presence of biochemical markers in urine samples which may 
be useful to establish the diagnosis of UTI [2]. Although many urine biomarkers for UTIs have 
recently been considered [45], markers that showed best results in diagnostic accuracy are nitrite 
and leukocyte esterase [6]. Although being cost-effective [46], such test shows low sensitivity 
that limits its clinical usefulness, [6] and analysis may be biased since a number of bacterial 
species are unreactive in these tests (e.g., no reduction of nitrates) [47, 48]. Furthermore, urine 
dipstick test does not detect bacteria, nor their concentration, which is essential to diagnose 
UTIs according to guidelines, and provides no information about antimicrobial susceptibility. 
Urine dipsticks are, anyway, cheap, easy to use, can be performed at doctor’s office, in pharma-
cies or at home (even though urine dipstick test is not intended for self-diagnosis purposes [49], 
are available without prescription and provide results of easy interpretation within minutes.
Among hospital tests routinely used for urine analysis, microscopy examination of urine sedi-
ment has since long time been used, also undergoing automation to improve results. Although 
sensitivity is high, specificity is too low for exclusive use in clinical settings. Moreover, such 
technique requires sample centrifugation, and experienced personnel is needed to avoid 
errors in microscopic examination [6].
Flow cytometry found applications in many fields, also including medical disciplines [50]. 
Automated platforms of urinary flow cytometry have been widely adopted by centralized 
laboratories [10]. Flow cytometry allows of rapid detection of bacteria, white blood cells, red 
blood cells, epithelial cells, casts, crystals, yeasts and spermatozoa. They offer the benefit of 
standardize urine sediment analysis and reduce the error associated with subjective interpre-
tation of results [51]. Nevertheless, the poor quality of available studies was confirmed in a 
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recent meta-analysis, which also showed current low accuracy and specificity of such method 
that should not be used as the sole screening tool for UTIs ([51], and references therein).
Dipslide technology has been proposed to simplify traditional culture-based methods: the test 
allows the detection of bacteria in liquid matrices by observing growth on different agar media 
(e.g., CLED agar and MacConkey agar) after immersion into sample and following 24-hour 
incubation. Overall, despite being simple to use and cost-effective, dipslide technology can 
only be considered as a guide to support further analyses: such test shows low accuracy when 
compared to the reference culture method [6], and no reliable detection of <104 CFU/ml can be 
obtained [7]. For this reason, dipslides are currently unsuited to routine use in clinical setting 
with further studies required to determine the best combination of culture media [6].
For the short term, molecular biology techniques such as real-time PCR could be used to 
complement conventional culture-based methods for pathogens identification, especially 
with regard to shortening the time to obtain results, shortening the time to decision of antibi-
otic therapy [32]. However, this method is limited by the broadness of the panel of pathogens 
included in the test, and both sensibility and specificity are low when compared to urine 
culture. Moreover, such technology requires many steps for sample preparation and does 
not allow a viable count, also considering that up to now the clearance of bacterial DNA 
from urine is unclear. The need for quantification in UTI diagnosis should drive future devel-
opments of commercial real-time PCR pathogen detection tools to include a quantification 
option [32].
In addition, possible new routes have been explored aiming to develop new clinical tools to 
help rapidly identify uropathogens, such as: the detection of volatile organic compounds in 
urine by gas chromatography and mass spectrometry and following comparison between 
profiles using compounds databases [52]; the use of Raman and Surface Enhanced Raman 
Spectroscopy, which can provide quantification and identification of bacteria populations 
and possibly assessment of antibiotic susceptibility, although results are still preliminary and 
must be significantly expanded [12]; the use of impedance spectroscopy to detect ultra-low 
concentrations of E. coli in human urine and provide quantification for UTI diagnosis [53].
Although rapid, these technologies do not provide microbiological diagnosis nor susceptibil-
ity information, which remain the cornerstone of diagnosis, particularly in settings of com-
plicated UTI [10].
In summary, laboratory urine culture remains the gold standard investigation for UTI diag-
nosis [6].
6. The importance of point-of-care tests in UTI diagnosis
Some tests have been developed aiming to provide rapid and accurate diagnostic informa-
tion to direct treatment decisions at the patient’s bedside, which seem to have yielded good 
consent among practitioners [54].
Urinary Tract Infection - The Result of the Strength of the Pathogen, or the Weakness of the Host20
Rapid and definitive near-the-patient diagnosis of UTI would have a favorable impact on 
its management [10]: a rapid turnaround of results could influence clinical decisions such as 
triage, referral, and decision to discharge the patient. Prompt clinical interventions could be 
provided by caregivers, meaning timely antibiotic treatment could be initiated and impre-
cise empirical treatment avoided [10, 55]. This would improve health outcome also pro-
viding diagnostics tools for limited-resource settings [55]. Point-of-care tests (POCTs) can 
provide considerable savings in health care costs by reducing the number of patients visiting 
health centers simultaneously improving the quality of life for patients by reducing their 
number of visits to health care facilities [55]. An early diagnosis based on POCTs can also 
enable clinicians to start antibiotic administration earlier and thereby increase chances of 
successfully treating the disease. In future, innovation through rapid and reliable POCTs is 
advisable, updating technologies to ensure efficient data management and simplify use by 
healthcare professionals, eventually lowering medical costs [55]. POCTs could allow a bet-
ter screening and follow-up of patients not only by hospitals, but also by pharmacies and 
general practitioners, helping decentralize diagnosis and therefore reduce the workload of 
laboratories, with consequent reduction of costs related to urine analysis and management 
of UTIs and reduction of human errors leading to mix-ups of patient samples sent to off-site 
laboratories [55].
Several POCT for UTIs have been developed and are currently commercially available. They 
can be distinguished in: (i) culture-based devices, (ii) (semi-)automated urine analyzers and (iii) 
enzymatic assays [56]. All culture-based devices allow semi-quantification of bacterial growth 
and evaluation of the infecting bacterial species. Most often, samples need to be cultured and 
appreciable bacterial growth can be achieved in not less than 16–24 hours. The (semi-)automated 
urine analyzers have the same read-out as the urine dipstick test and UTI diagnosis is based on 
the presence of markers such as nitrites and leukocytes. Although the human error involved in 
visual interpretation can be eliminated and results can be obtained in 1–2 minutes, these tests do 
not significantly improve current practice exhibiting very low sensitivity and limited positive 
predictive value. The same problem has been reported for enzymatic assays [57–61].
Biosensors offer a promising approach for improving molecular diagnostic in POC settings 
[10]. Biosensors are binary systems composed of a recognition and a transducer element that 
can generate a measurable proportional signal following binding of the target analyte to the 
recognition element (e.g., antibody, enzyme), which allows quantitative detection of a biolog-
ical entity [10]. Even though biosensors technology has been applied successfully to the field 
of clinical diagnostic (e.g., blood glucose and pregnancy tests), no such tests have been imple-
mented to date to improve routine diagnosis of UTIs [55]. Indeed, key features of biosen-
sors, such as portability, rapidity, and cost-effectiveness in comparison with their macro-scale 
counterparts, could be crucial for the development of a POCT for UTI pathogens identifica-
tion and antimicrobial susceptibility assessment. Nevertheless, considering the urine matrix, 
such biosensors would require multistep sample preparation with amplification/enrichment 
steps to improve target detection, and such biological matrix could impair sensor perfor-
mance with its variations in biochemical parameters (e.g., inhibitors, non-specific binding). 
Moreover, such tests should have a multiplex approach to ensure identification of a broad 
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panel of pathogens in different clinical scenarios, and should provide antimicrobial suscepti-
bility testing to drive  treatment, but genetic non-culture based approaches are limited by the 
fast evolution rate of defense mechanisms among bacteria. Biosensors POCTs could anyway 
complement reference methods helping saving resources in terms of materials, money and 
time, because rapid, simple and cost-effective tests could optimize further analyses therefore 
reducing the burden on laboratories [10].
The Micro Biological Survey (MBS) POCT “UTI CHECK” appears to hold good promise 
for early detection and antimicrobial susceptibility profiling of uropathogens. The MBS 
method allows rapid and accurate bacterial quantification through an automated colorimet-
ric culture-based test; urine samples are inoculated into disposable ready-to-use reaction 
vials, which color will change thanks to redox indicators following bacterial growth after 
incubation (see Figure 1). Results of preliminary in vitro validation studies [62, 63] showed 
that the results obtained with this method are comparable to the reference culture-based 
methods.
Such findings encouraged further research in hospital settings, and clinical trials have been 
carried out [31] in which the efficacy of the MBS POCT was compared to the reference 
method, used in hospital routine, and other methods, such as urine dipsticks: the MBS POCT 
Figure 1. MBS “UTI CHECK.” MBS “UTI CHECK” is an automated colorimetric culture-based test. It is composed 
by mono-use, disposable and ready-to-use reaction vials (right) in which 1 ml of urine can be inoculated without any 
preliminary treatment. Up to eight urine-inoculated reaction vials can be independently allocated in an automatic 
thermostated optical reader (left) that it is able to detect color change induced by the growth of bacteria and automatically 
correlates the time required for color change with the number of bacteria present in the urine samples. Different vials 
contain selected antibiotics and the occurrence of the color change in the presence of antibiotics indicates antibiotic 
resistance of bacteria present into the urine sample.
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Product Manufacturer/
location
Description of 
device
Analysis 
time
Additional 
equipment 
required
Positive result 
outcomes
Method 
principle
Number 
of samples 
tested;
Test 
population
Threshold for 
significant 
growth
Accuracy Sensitivity 
(%) (95% 
CI)
Specificity 
(%) (95% 
CI)
Ref
FLEXICULT™ Statens Serum 
Institut 
Diagnostica/
Denmark
Chromogenic 
agar plate with 
6 segments – 5 
evaluating 
anti-biotic 
sensitivities 
and 1 control 
segment
24 hours Incubator Semi-
quantification 
of bacterial 
growth, 
evaluation of 
the species 
present, and 
assessment of 
sensitivity to 
the antibiotics 
in each of the 
plate segments
Microbial 
culture and 
susceptibility 
testing
N = 200/124 
(outpatient 
setting)/76 
(secondary 
care setting)
≥105 CFU/ml — 87.0% 
(67.9–95.5)
83.2% 
(74.7–89.2)
[23]
Uricult Trio Orion 
Diagnostics/
Finland
Plastic slide 
with two 
opposing agar 
media
16–24 hours 
when 
incubated 
at 36.8 °C 
or 1–3 days 
at room 
temperature
Incubator Semi-
quantification 
of bacterial 
growth, 
evaluation of 
the species 
present
Microbial 
culture
198 (pediatric 
patients aged 
0–7)
≥104 CFU/ml — 68% 82% [26]
434 (primary 
health care 
setting)
≥103 to 
≥105 CFU/ml 
for doubtful 
uropathogens
88% 88% 90% [27]
DipStreak 
(Chromostreak)
Novamed/
Israel
Plastic paddle 
with two 
opposing agar 
media, housed 
in a closed 
transparent 
plastic tube
18–24 hours Incubator Semi-
quantification 
of bacterial 
growth, 
evaluation of 
the species 
present
Microbial 
culture
N = 1070 (251 
hospitalized 
patients 
and 819 
outpatients)
>105 CFU/
ml (single 
organism + 
mixed culture)
98% 95.7% 99.2% [28]
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Product Manufacturer/
location
Description of 
device
Analysis 
time
Additional 
equipment 
required
Positive result 
outcomes
Method 
principle
Number 
of samples 
tested;
Test 
population
Threshold for 
significant 
growth
Accuracy Sensitivity 
(%) (95% 
CI)
Specificity 
(%) (95% 
CI)
Ref
DiaSlide Novamed/
Israel
Hinged plastic 
case containing 
two opposing 
agar media
24 hours Incubator Semi-
quantification 
of bacterial 
growth
Microbial 
culture
473 
(prescreened 
hospital urine 
specimens 
using 
UriScreen)
≥104 CFU/ml — 98.3% 97.5% [29]
onSite Trek 
Diagnostics 
System/USA
Hinged plastic 
case containing 
two opposing 
agar media
Not specified Incubator Semi-
quantification 
of bacterial 
growth, 
evaluation of 
the species 
present
Microbial 
culture
MBS
UTI CHECK
MBS srl/Italy Mono-use 
disposable 
vials for 
chromogenic 
analysis
3–5 hours MBS 
Multireader
Semi-
quantification 
of bacterial 
load, 
assessment 
of sensitivity 
to selected 
antibiotics
Measure of 
the catalytic 
activity of 
redox enzymes 
of bacteria
N = 223 
(emergency 
department)
≥105 CFU/
ml (single 
organism + 
mixed culture)
99% 92.6% 
(75.7–99.1)
100% 
(94.9–100)
[17]
Table 1. Features of main POCTs for UTI diagnosis.
Urinary Tract Infection - The Result of the Strength of the Pathogen, or the W
eakness of the Host
24
showed high accuracy, sensitivity and specificity, comparable to the reference method’s and 
higher than urine dipsticks’ [31]. Although not providing bacterial identification, MBS “UTI 
CHECK” allows bacteria detection and quantification in urine samples. Preliminary results 
showed that this POCT can provide uropathogens’ susceptibility pattern to a panel of anti-
biotics. The analytical time required for UTI diagnosis is usually less than 3 hours (up to 
5–6 hours when the bacterial load is equal or less than 1 × 105 CFU/ml) and antimicrobial 
susceptibility assessment is obtained in less than 10 hours, which could guide downstream 
medical decisions with crucial information within few hours. Notably, this method features 
cost-effectiveness, user-friendliness, portability, easy interpretation of results, which all can 
lead to successful use at the patient’s bedside [31]. The MBS point-of-care testing device could 
be developed into a valuable aid for the management of UTIs, possibly addressing more pre-
cise diagnosis and appropriate therapy also proving useful in treatment outcome evaluation. 
Features of main POCTs available on market, including MBS “UTI CHECK,” are summarized 
in Table 1.
7. Conclusions
To date, hospital settings rely mainly on laboratory analysis following urine culture reference 
method; this approach requires a considerable effort in terms of workload and up to 3 days 
to achieve results. Furthermore, it can lead to unnecessary antimicrobial overuse which ulti-
mately promotes the emergence of resistance [31].
The unnecessary use of antibiotic treatment may be minimized following two roads: on one 
hand by the establishment of antibiotic stewardship programs which require healthcare staff 
involvement in regular training in best use of antimicrobial agents for an improved adherence 
to local, national or international guidelines and regular consultation with infectious diseases 
physicians, with audit [6]; on the other hand by improving diagnostic pathways [1], possi-
bly relying on use of POCTs that feature incorporation of pathogen identification with anti-
microbial susceptibility testing, sufficiently versatile to be adaptable for different pathogen 
profiles in different clinical scenarios [10]. The advent of accurate and robust POCTs could 
allow a more rational screening before treatment or admission and to improve follow-up of 
patients for treatment outcome evaluation and for monitoring of antimicrobial prescribing 
performance and local pathogen resistance profiles [6].
Such approach could ultimately lead to treatment customization according to individual 
patients’ characteristics through fast antibiotic susceptibility testing results [44], with the ulti-
mate aim of improving patients’ welfare and reduce healthcare costs.
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